{"doi":"10.17615/vme9-c859","title":"Effect of Thromboprophylaxis on Clinical Outcomes After COVID-19 Hospitalization","abstract":"BACKGROUND: Patients hospitalized with COVID-19 have an increased incidence of thromboembolism. The role of extended thromboprophylaxis after hospital discharge is unclear. OBJECTIVE: To determine whether anticoagulation is superior to placebo in reducing death and thromboembolic complications among patients discharged after COVID-19 hospitalization. DESIGN: Prospective, randomized, double-blind, placebo-controlled clinical trial. (ClinicalTrials.gov: NCT04650087). SETTING: Done during 2021 to 2022 among 127 U.S. hospitals. PARTICIPANTS: Adults aged 18 years or older hospitalized with COVID-19 for 48 hours or more and ready for discharge, excluding those with a requirement for, or contraindication to, anticoagulation. INTERVENTION: 2.5 mg of apixaban versus placebo twice daily for 30 days. MEASUREMENTS: The primary efficacy end point was a 30-day composite of death, arterial thromboembolism, and venous thromboembolism. The primary safety end points were 30-day major bleeding and clinically relevant nonmajor bleeding. RESULTS: Enrollment was terminated early, after 1217 participants were randomly assigned, because of a lower than anticipated event rate and a declining rate of COVID-19 hospitalizations. Median age was 54 years, 50.4% were women, 26.5% were Black, and 16.7% were Hispanic; 30.7% had a World Health Organization severity score of 5 or greater, and 11.0% had an International Medical Prevention Registry on Venous Thromboembolism risk prediction score of greater than 4. Incidence of the primary end point was 2.13% (95% CI, 1.14 to 3.62) in the apixaban group and 2.31% (CI, 1.27 to 3.84) in the placebo group. Major bleeding occurred in 2 (0.4%) and 1 (0.2%) and clinically relevant nonmajor bleeding occurred in 3 (0.6%) and 6 (1.1%) apixaban-treated and placebo-treated participants, respectively. By day 30, thirty-six (3.0%) participants were lost to follow-up, and 8.5% of apixaban and 11.9% of placebo participants permanently discontinued the study drug treatment. LIMITATIONS: The introduction of SARS-CoV-2 vaccines decreased the risk for hospitalization and death. Study enrollment spanned the peaks of the Delta and Omicron variants in the United States, which influenced illness severity. CONCLUSION: The incidence of death or thromboembolism was low in this cohort of patients discharged after hospitalization with COVID-19. Because of early enrollment termination, the results were imprecise and the study was inconclusive. PRIMARY FUNDING SOURCE: National Institutes of Health.","journal":"UNC Libraries","year":2025,"id":580829,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9627,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":334842,"name":"Lisa Baumann Kreuziger","orcid":"0000-0002-1171-0548","position":1,"is_corresponding":false},{"id":1492251,"name":"Annie Pennella","orcid":null,"position":2,"is_corresponding":false},{"id":740970,"name":"Nancy L. Shapiro","orcid":"0000-0002-0792-0235","position":3,"is_corresponding":false},{"id":268710,"name":"Alexandra Weissman","orcid":"0000-0002-3350-899X","position":4,"is_corresponding":false},{"id":642641,"name":"Deborah Siegal","orcid":"0000-0003-3806-3245","position":5,"is_corresponding":false},{"id":1492252,"name":"ACTIV-4C Study Group","orcid":null,"position":6,"is_corresponding":false},{"id":892699,"name":"Gervasio A. Lamas","orcid":"0000-0002-6678-2813","position":7,"is_corresponding":false},{"id":288739,"name":"Thomas L. Ortel","orcid":"0000-0001-6193-4585","position":8,"is_corresponding":false},{"id":802958,"name":"M. Margaret Knudson","orcid":"0000-0002-6466-5816","position":9,"is_corresponding":false},{"id":499268,"name":"Andrew J. Alexander","orcid":"0000-0002-0897-020X","position":10,"is_corresponding":false},{"id":1096266,"name":"Lingyun Lyu","orcid":null,"position":11,"is_corresponding":false},{"id":249626,"name":"Raj S. Kasthuri","orcid":"0000-0001-6672-3082","position":12,"is_corresponding":false},{"id":74896,"name":"Tracy Y. Wang","orcid":null,"position":13,"is_corresponding":false},{"id":1492253,"name":"Bassel Atassi","orcid":null,"position":14,"is_corresponding":false},{"id":694696,"name":"Andrei Kindzelski","orcid":null,"position":15,"is_corresponding":false},{"id":32255,"name":"Mark W. Geraci","orcid":"0000-0002-2280-3424","position":16,"is_corresponding":false},{"id":244904,"name":"Eric Leifer","orcid":"0000-0001-6888-8307","position":17,"is_corresponding":false},{"id":846576,"name":"Lana Wahid","orcid":"0000-0002-2160-3287","position":18,"is_corresponding":false},{"id":313765,"name":"Alison Morris","orcid":"0000-0002-7290-6536","position":19,"is_corresponding":false},{"id":1492254,"name":"Janice W. Lawson","orcid":null,"position":20,"is_corresponding":false},{"id":388936,"name":"Brendan M. Everett","orcid":"0000-0002-6331-5224","position":21,"is_corresponding":false},{"id":65482,"name":"Kevin J. Anstrom","orcid":"0000-0001-6452-2172","position":22,"is_corresponding":false},{"id":654968,"name":"Jungnam Joo","orcid":"0000-0001-6961-8122","position":23,"is_corresponding":false},{"id":804351,"name":"Bela Patel","orcid":"0000-0001-5804-5226","position":24,"is_corresponding":false},{"id":449597,"name":"Abdus S. Wahed","orcid":"0000-0001-6911-7221","position":25,"is_corresponding":false},{"id":1121838,"name":"Peter Miller","orcid":"0000-0002-6896-5437","position":26,"is_corresponding":false},{"id":979074,"name":"John G. Quigley","orcid":"0000-0003-3116-4545","position":27,"is_corresponding":false},{"id":286934,"name":"Deborah Martin","orcid":null,"position":28,"is_corresponding":false},{"id":250091,"name":"Jerry A. Krishnan","orcid":"0000-0001-5525-4778","position":29,"is_corresponding":false},{"id":1492250,"name":"Lopez-Sendon, Jose","orcid":null,"position":0,"is_corresponding":true}],"reference_count":0,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-07-19T02:58:43.046112Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}